Floatz logo

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE

Anxiety Disorders

Hannover Medical SchoolSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Anxiety Disorders cohort.

Asset / SponsorPhaseRating
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 4BBB
Risperdal
Tianjin Medical University General Hospital
Phase 4BBB
Olanzapine
Tianjin Medical University General Hospital
Phase 4BBB
FLUOXETINE
Hannover Medical School
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Theresa Jacob, PhD, MPH
Phase 4BBB

View all 50 →

Same molecule, other indications

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE is also rated in:

FlupentixolDormant
B
Indicative ·
62 / 100
View asset →
Antipsychotic AgentsDormant
B
Indicative ·
62 / 100
View asset →
central nervous system disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →